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Abstract
Nigeria has an emerging problem with multidrug-resistant tuberculosis (MDR-TB). Whole-
genome sequencing was used to understand the epidemiology of tuberculosis and genetics
of multi-drug resistance among patients from two tertiary referral centers in Southwest Nige-
ria. In line with previous molecular epidemiology studies, most isolates of Mycobacterium
tuberculosis from this dataset belonged to the Cameroon clade within the Euro-American
lineage. Phylogenetic analysis showed this clade was undergoing clonal expansion in this
region, and suggests that it was involved in community transmission of sensitive and multi-
drug-resistant tuberculosis. Five patients enrolled for retreatment were infected with pre-
extensively drug resistant (pre-XDR) due to fluoroquinolone resistance in isolates from the
Cameroon clade. In all five cases resistance was conferred through a mutation in the gyrA
gene. In some patients, genomic changes occurred in bacterial isolates during the course of
treatment that potentially led to decreased drug susceptibility. We conclude that inter-patient
transmission of resistant isolates, principally from the Cameroon clade, contributes to the
spread of MDR-TB in this setting, underscoring the urgent need to curb the spread of multi-
drug resistance in this region.
Introduction
In humans and other animals, tuberculosis (TB) is caused by a group of related mycobacterial
species that form the Mycobacterium tuberculosis complex (MTBC) [1, 2]. The human-associ-
ated species M. tuberculosis and M. africanum form seven distinct phylogenetic lineages that
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are believed to have co-evolved with humans over millennia [3–7]. Lineages 2 (which includes
the Beijing clade) and 4 (the Euro-American Lineage) are more widespread globally than other
MTBC lineages and have been found to be more pathogenic and transmissible [8]. The Camer-
oon clade from Lineage 4 is the most common genotype of M. tuberculosis isolated from
patients with active pulmonary tuberculosis in parts of West Africa including Nigeria [9–13].
A unique feature of MTBC in West Africa is the presence of two M. africanum lineages,
human-associated ecotypes that cause up to 40% of tuberculosis in parts of West Africa [14].
Although mortality attributed to TB has halved since 1990, it remains a leading cause of
death by infectious disease globally [15]. In 2015, there were an estimated 10.4 million new
cases of, TB globally, resulting in 1.5 million deaths [16]. Nigeria is in the top-20 list for TB,
TB/HIV and MDR-TB burden [17–19]. It was estimated that in 2012 only 3% cases of MDR-
TB that occurred in Nigeria were detected and reported [20]. Diagnosis of MDR-TB is chal-
lenging because traditional phenotypic approaches to sensitivity testing in tuberculosis are
slow and laborious. Bacterial whole-genome sequencing (WGS) offers early detection of resis-
tance to both first- and second-line drugs, making it useful for diagnosing and guiding treat-
ment of MDR-TB [21, 22].
In high-burden settings such as Nigeria, inter-patient transmission is the main source of
MDR-TB infection [23]. Studies have employed WGS to infer transmission of M. tuberculosis
by combining genetic distances (as a measure of single nucleotide variants), epidemiological
data and/or phylogenetic data [24]. The SNV threshold for inferring transmission varies with
location and the diversity of the dataset [24]. In 2013, Walker and colleagues proposed that iso-
lates from epidemiologically linked patients that differed by 5 single nucleotide variants
(SNVs) or fewer were indicative of inter-patient transmission of TB [25]. Although some stud-
ies have limited inference of transmission to isolates that differ by as few as 1,2 or 3 SNVs [26–
28], Guerra-Assunc¸ão and colleagues inferred transmission from epidemiologically linked
cases between isolates differing by as many as 10 SNVs [29].
Here, we present whole-genome analyses of MTBC isolates that were collected from two
South-West Nigerian TB referral centers as part of the WANETAM MDR-TB surveillance.
Our results shed light on the genomic changes underlying drug resistance and place these iso-
lates within a phylogenetic context in the MTBC. Our study represents a proof-of-concept to
demonstrate the feasibility of using WGS to gains insights into the transmission and evolution
of MDR-TB in West Africa.
Methods
Isolates and antimicrobial susceptibility testing
Between December 2011 and July 2014, 177 MTBC isolates were sent to the MRC Unit the
Gambia (MRCG) from tertiary tuberculosis referral centers at two sites in South-West Nigeria:
The Nigerian Institute of Medical Research, Lagos and the University College Hospital, Iba-
dan. These isolates were recovered from patients with active pulmonary TB that reported to
the referral centers between 2011 and 2014. Isolates were tested for viability and anti-microbial
susceptibility at MRCG [30]. Break-point susceptibility testing for the first-line drugs strepto-
mycin (STR, 1 μg/mL), isoniazid (INH, 0.1 μg/mL), rifampicin (RIF, 1μg/mL), and ethambutol
(EMB, 5 μg/mL) was done using the MGIT 960 system (Becton Dickinson, Sparks, MD, USA)
according to manufacturer’s instructions [31]. MDR strains were further tested using the
MGIT system for susceptibility to kanamycin (KAN, 2.5 μg/mL) capreomycin (CAP, 2.5 μg/
mL), ofloxacin (OFX, 2 μg/mL), and ethionamide (ETH, 5 μg/mL) (Sigma-Aldrich, St. Louis,
Mo, USA) according to WHO guidelines [32].
Genomic insights into MDR-TB in Nigeria
PLOS ONE | https://doi.org/10.1371/journal.pone.0184510 September 19, 2017 2 / 12
Abbreviations: TB, Tuberculosis; MDR-TB,
Multidrug resistant tuberculosis; Pre-XDR-TB, Pre-
extensively drug resistant tuberculosis; XDR-TB,
Extensively drug resistant tuberculosis; MTBC,
Mycobacterium tuberculosis complex; WGS,
Whole genome sequencing; WANETAM, West
African Nodes of Excellence for Tuberculosis AIDS
and Malaria; MIRU VNTR, Mycobacterial
Interspersed Repetitive Units Variable Number
Tandem Repeats; CTAB, Cetyltrimethyl ammonium
bromide; MRCG, MRC Unit the Gambia; SNV,
Single nucleotide variant; MAF1, Mycobacterium
africanum West Africa 1; DOTS, Directly observed
treatment short course.
WGS was performed on 75 MTBC isolates (43 MDR and 32 non-MDR) from 177 stored
isolates. TB patients recruited at the Nigerian Institute of Medical Research were sampled at
multiple time points during treatment. Therefore, for some patients, two or three isolates
obtained at different time points were sequenced. The dates presented show when the samples
were received at the MRCG. Thus, in some cases it was possible to infer the order of sampling
based on sample reception date, even though the exact date of sample collection could not be
established. The Joint Gambia Government/MRC Ethics Committee, the University of Ibadan
and University College Hospital, Ibadan Joint ethical Review Committee and the Nigerian
Institute for Medical Research Institutional board approved the study protocols.
Genomic DNA extraction and sequencing
Genomic DNA was extracted from Middlebrook 7H9 liquid cultures that had been incubated
for 5–8 weeks using acetyltrimethyl ammonium bromide (CTAB) method [33]. Genomes
were sequenced on the MiSeq with the V2 reagent kit (2 x 250 bp) following Nextera XT
library preparation according to the manufacturer’s instructions (Illumina, Little Chesterford,
UK). Sufficient coverage (>10X) could not be obtained on two isolates, so the final dataset
contained 73 isolates of MTBC.
Phylogenetic analysis, drug susceptibility and lineage determinants
The sequencing reads were mapped to the M. tuberculosis H37Rv reference genome and vari-
ant sites were called as previously described [34]. Briefly, variants were called on sites that were
covered by at least two reads in each direction, had a Q30 mapping score> 30, and were sup-
ported by > 75% of the reads. The maximum likelihood phylogeny was reconstructed from
SNVs in the core genome with RAxML using a general time-reversible model of substitution
[35]. The phylogenetic tree was visualized with FigTree and manually annotated.
The user-friendly web tools Kvarq, Phyrese and TBProfiler were used to infer phylogenetic
lineage from sequencing reads [36–38]. Kvarq classified samples into the seven global lineages,
while Phyrese and TBprofiler offered more highly resolved classification of strains into the
sub-lineages of the Euro-American super-lineage, Lineage 4 (S1 Table). All three tools reported
known resistance mutations (S2 Table).
Results
Genome sequences from 73 clinical isolates of MTBC, obtained from 63 TB patients were ana-
lysed (Table 1). Isolates from the same patient taken at different times were classed as a single
clinical case. Isolates were mapped to the H37Rv reference genome with an average coverage
of 49.6x (range 24.3 to 78.4). The phylogeny was reconstructed from 8667 variant core genome
sites, excluding known repetitive regions and regions of deletion.
Phylogenetic analysis
The Euro-American super-lineage (lineage 4) was predominant, found in 56 cases (88.9%).
The Cameroon sub-lineage of lineage 4 was associated with 37 cases (59%: 52% and 67% of
MDR and non-MDR cases respectively) (Table 2). Our tree topology (Fig 1) places our isolates
from the Cameroon sub-lineage in a monophyletic clade, with an average within-clade core-
genome pairwise SNV distance of 97 (range: 1–195). Other genotypes from lineage 4, includ-
ing the H37Rv, LAM, TUR, Ghana, Haarlem and X-type sub-lineages, accounted for 20 cases
(32% of cases).
Genomic insights into MDR-TB in Nigeria
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Six patients (9.5% of cases) were infected with isolates from the M. africanum sub-lineage 1
(MAF1), also called the West Africa 1 lineage or Lineage 5. Two serial MAF1 isolates recovered
from a retreatment cases from Lagos were identical. However, these isolates differed from an
isolate recovered from a retreatment case in Ibadan by 16 SNVs in the core genome. Although
this is above the threshold for recent inter-patient transmission, this observation suggests that
the MAF1 lineage has been involved in transmission of MDR-TB in the recent past. One
patient was infected by an isolate belonging to M. bovis, a lineage usually associated with ani-
mal infection, which was placed as an outlier on the phylogenetic tree.
Microevolution: Genomic changes during treatment and transmission
We report two scenarios where closely related pairs of isolates were recovered from different
patients and one of the isolates had acquired resistance mutations (Fig 2). The MDR strains
NG9 and NG23 were isolated from two patients that were enrolled in Lagos in 2011 and 2012,
respectively. These strains differed at a single nucleotide site in their core genomes: the NG23
isolate has acquired the katG mutation L587P. Similarly NG1 and NG31 were near-identical
MDR strains isolated from different patients. Both isolates harbored canonical mutations in
Table 1. Summary of patient metadata for 63 patients included in the study.
Ibadan Lagos
MDR Non-MDR MDR Non-MDR
Total 6 15 30 12
HIV Status Negative 6 15 21 8
Not Done 2
Positive 7 4
Gender Female 4 3 11 6
Male 2 12 18 6
Treatment History Failure 2 3
New 8 4 4
Relapse 2 4
Retreatment 6 7 21 1
Age (years) 0–15 1 1 1
16–30 1 6 10 1
Above 30 5 8 18 10
https://doi.org/10.1371/journal.pone.0184510.t001
Table 2. Summary of the prevalence of MDR within the different clades among 63 patients.
Lineage Clade MDR Non-MDR
M. bovis Bovis 1
Lineage 4 Cameroon 19 18
Uganda 2 4
Ghana 2
X-type 1
H37Rv 1
Haarlem 2 1
LAM 2 2
TUR 2
Lineage 5 West Africa 1 5 1
Grand Total 36 27
https://doi.org/10.1371/journal.pone.0184510.t002
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the embB codon 306. However, NG1 acquired a further mutation in the embA promoter region
and consequently NG1 was ethambutol-resistant, while NG31 was susceptible to ethambutol
according to phenotypic testing.
An MDR strain belonging to the Ghana genotype was isolated from a patient who was
enrolled in 2011 for retreatment. Strains NG16, NG43 and NG4 were isolated from this patient
on successive hospital visits. All three strains were susceptible to fluoroquinolones on pheno-
typic testing, but the final isolate sampled from the patient in 2013 (NG4) had acquired a
mutation associated with low-level fluoroquinolone resistance (gyrB E501D) and should there-
fore be classified as pre-XDR TB according to its genotype (Fig 2).
Fig 1. Maximum likelihood phylogeny of Mtb isolated from patients with active pulmonary TB.
Branches are coloured by lineage and tips are coloured by the sub-clades within the lineages. A star marks
almost identical genomes (<3 SNVs difference) isolated from different patients. Adjacent data links strains to
patient metadata: MDR and pre-XDR status, treatment status, HIV status, sex and recruitment site and date
of sample reception.
https://doi.org/10.1371/journal.pone.0184510.g001
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Molecular mechanisms propagating multidrug and pre-extensively drug
resistant TB
MDR was present in 39 clinical cases, while three clinical cases presented with resistance to
isoniazid but not to rifampicin. Looking for known resistance mutations in the genome
sequence provided insights into the molecular mechanisms causing multidrug resistance in
our dataset (Fig 3). At least one known isoniazid-resistance mutation was found in 35 out of
39 clinical cases where isoniazid resistance was reported from phenotypic susceptibility testing.
Thirty-three cases of isoniazid resistance were associated1 resistance mutations in katG or
inhA. Mutations at codon 315 of katG were present in 21 isoniazid resistant clinical cases and
one case reported as isoniazid-sensitive. Mutations in the inhA and ahpC promoter regions
were combined with other resistance mutations in some isoniazid resistant strains, while a
mutation in ahpC was the only resistance mutation found in two MDR clinical cases.
All isolates from rifampicin-resistant clinical cases carried at least one resistance mutation
in the rpoB gene. In two clinical cases, a mutation in the rpoB gene was complemented by an
apparent epistatic mutation in the rpoC gene. At least one mutation in the embCAB operon
was observed in 30 out of 34 clinical cases of MDR. At least one resistance mutation in the
embCAB operon was found in 13 out of 16 (81%) ethambutol-resistance cases, while 17 out of
44 (39%) sensitive cases were associated with at least one mutation on the operon. Mutations
at codons 306, 497 and 406 of the embB gene were detected among both ethambutol-resistant
Fig 2. Microevolution of Mtb within patients during the course of treatment. Phylogenetic tree is linked to
resistance profile of isolates that were paired with at least one near-identical genome (<3 SNVs difference). These
genomes represent isolates from patients that were samples at least twice during the course of treatment as well
as almost identical genomes from different patients. The resistance profiles for Streptomycin (Str), Isoniazid (INH),
Rifampicin (RIF), Ethambutol (EMB), Flouroquinolones (FQ), Capreomycin (CAP), KANAMYCIN (KAN) and
Ethionamide (ETH) are shown. The presence of resistance mutations to each drug are listed next to a bar
indicating phenotypic susceptibility.
https://doi.org/10.1371/journal.pone.0184510.g002
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and ethambutol-sensitive isolates. Only 12 out of 29 (41.4%) cases of streptomycin resistance
were associated with a known resistance mutation.
Five clinical cases of pre-extensively drug resistant (pre-XDR) were associated with fluoro-
quinolone resistance based on phenotypic testing. All five clinical cases of pre-XDR-TB
occurred among retreatment cases, were associated with isolates from the Cameroon clade
that were linked to a mutation in the gyrA gene. Notably, gyrAmutations that confer low-level
fluoroquinolone resistance were present in two fluoroquinolone-susceptible MDR isolates
(NG6 and NG70),. One of these isolates (NG70) also harbored the tlyA (Rv1694) N236K muta-
tion that confers resistance to capreomycin. This isolate would be classified as extensively drug
resistant tuberculosis (XDR-TB) on grounds of genotype, but was apparently sensitive to all
second line drugs by phenotypic testing. Of nine ethionamide-resistant isolates, five were
linked to at least one mutation in the inhA gene or the inhA promoter region FABG1.
Discussion
The high prevalence of Cameroon clade strains in this dataset (59%) is similar to recent esti-
mates from Nigeria based on spoligotyping [12]. There is evidence that the Cameroon lineage
has been spreading within the community. Within the Cameroon clade, there were four
instances where closely related genomes (< 3 SNVs difference) were recovered from two dif-
ferent patients (marked by  on Fig 1). The SNV difference between these pairs of isolates falls
within the threshold for inter-patient transmission set by Walker and colleagues [25].
There was less evidence of ongoing transmission among other Euro-American sub-line-
ages, since isolates from different patients in these lineage all differed by at least 30 SNVs. The
exception was, in the TUR sub-lineage, two MDR strains isolated from different patients dif-
fered by only 18 SNVs. However, the cross-sectional nature of patient recruitment and the lack
of epidemiological and demographic data on the patients hampered our ability to infer chains
of inter-patient transmission.
The reasons for the selection and dissemination of the Cameroon genotype in West Africa
remain unclear, highlighting the need to investigate its evolutionary origins through WGS [10,
12]. In Ghana, the Cameroon clade is believed to have been introduced through the south of
Fig 3. Molecular mechanisms of resistance to first- and second-line anti-TB drugs. A heatmap showing the phenotypic susceptibility profiles to first-
and second-line anti-TB drugs and the presence of known resistance mutations. Blue = phenotypically susceptible, Red = phenotypically resistant,
Black = presence of resistance mutation, white = absence of resistance mutation and grey = no phenotypic testing.
https://doi.org/10.1371/journal.pone.0184510.g003
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the country, where a higher proportion of infection is associated with this clade than in the
north [39]. To our knowledge this is the largest collection of genome sequences from the Cam-
eroon clade that has been analysed. This study suggests that this genotype is on the rise and is
an important source of MDR-TB in Southwest Nigeria. Insights into the evolution of MTBC
lineages that are endemic to West Africa are rare but more will emerge as more genomic epi-
demiology studies are performed in the region.
M. africanum remains an important cause of tuberculosis in West Africa [12, 39] despite
reports of a diminishing presence in some regions [40]. Our findings suggest that multidrug
resistant MAF1 isolates have been transmitted within this setting during the recent past. The
prevalence of the M. africanum sub-lineage MAF1 in this dataset (9.5%) is lower than a recent
estimate [12] and this may be due to variable prevalence of MAF1 in different regions of the
country.
We report genomic changes that led to worsening drug resistance phenotypes through
acquisition of resistance mutations. These findings underscore the adverse consequences of
delayed diagnosis of resistance, ineffective treatment, and treatment interruptions or failure.
Nigeria has implemented the WHO recommended Directly Observed Treatment Short Course
(DOTS) since 1996. Despite efforts to control TB, interruption of treatment has been attrib-
uted to a number of factors including lack of knowledge of duration of treatment, living far
from hospital, inability to afford transport and abandoning treatment due to feeling better
[41]. Going forward, there is a need to investigate the acquisition of drug resistance mutations
in West-African lineages, such as the Ghana and Cameroon genotypes.
Early diagnosis of MDR-TB can be instrumental in ensuring treatment success. The WHO
recommends rapid testing for at least rifampicin resistance at the time of diagnosis [42]. The
implementation of Xpert1 MTB/RIF (Cepheid Inc.) for rapid detection of Mycobacterium
tuberculosis complex (MTBC) and rifampicin resistance has been intensified in Nigeria to
good effect [43, 44]. However, Xpert1 needs to be complemented with additional resistance
testing [45]. The Hain MTBDR plus kit is a rapid tool for early detection of drug resistance in
MTBC using molecular probes. For predicting isoniazid resistance, it has probes that detect
the katG S315T resistance mutation, as well as resistance mutations in the inhA promoter
region.
Routine in situ use of bacterial whole-genome sequencing is not yet feasible in a low-
resource setting like Nigeria for a number of reasons: inconsistent electricity supply, lack
of funds for sequencers and reagents and paucity of trained technicians who can perform
library preparations, sequencing and downstream bioinformatics analysis. Culture facili-
ties are also scarce, so the most practical method for diagnosis of MDR-TB probably
remains genotypic testing by commercially available tests such as the Xpert MTB/RIF and
Line Probe Assays. However WGS can contribute towards understanding the epidemiol-
ogy of MTBC in Nigeria in a research capacity. South Africa, an African country with a
comparably sized economy, has managed to make extensive use of WGS of local TB iso-
lates [46].
Conclusion
Transmission of MDR-TB is an ongoing phenomenon in our study sites in Southwest Nigeria
and this requires urgent intervention. Our data suggests that the Cameroon clade is involved
in transmission of MDR-TB in this setting. Our study underscores the urgent need for routine
drug susceptibility testing in Nigeria and more concerted efforts to ensure that patients are put
through the full course of treatment. These measures will give patients a better chance of sur-
vival and will help to curb the spread of MDR-TB.
Genomic insights into MDR-TB in Nigeria
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Study limitations
In the absence of epidemiological and patient demographic information, it was not possible to
infer with certainty inter-patient transmission based solely on genome sequences. The small
sample size presents a major limitation to our study and our ability to infer conclusions. Our
dataset was not powered to infer the population structure or the prevalence of drug resistance
in the community since patients were recruited only from referral hospitals—to determine the
prevalence of MDR-TB, a de novo cross-sectional sampling strategy would have to be imple-
mented. Furthermore the proportion of MDR-TB isolates that have been genome-sequenced
is higher than their prevalence because the initial emphasis of this study was on MDR-TB.
Nonetheless, we provide evidence of transmission of MDR-TB and worsening drug resistance
during the course of treatment from a low-resource, high-TB burden setting. The small sample
size limited our ability to detect novel resistance mutations. The resistance prediction was
restricted to mutations that were present in the databases used by the three software, if other
loci were probed the sensitivity of our methods relative to phenotypic testing might have been
improved.
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